Product imageResearch use only

CAT. NO. DC57006Featured

L319

Research highlights

55/10/32.5/2.5 mol% formulationpKa 6.38; FVII ED50 <0.01 mg/kg~60 nm; >90% siRNA entrapmentRapid elimination and NHP TTR study

Pack size & price

USD

Add the cited formulation componentsSelected L319 pack + every supporting component at 100 mg each+US$450 / set

Supporting components

DSPC DC57005 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$450

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

L319 (LIPID 319) is a novel ionizable, biodegradable lipid for delivery of short interfering RNAs (siRNAs). L319-LPN displays rapid elimination with pKa of 6.38 and also shows well tolerated up to 10 mg/kg.

CAS No.	1351586-50-9
Chemical Name	L319
Synonyms	di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate;bis[(Z)-non-2-enyl] 9-[4-(dimethylamino)butanoyloxy]heptadecanedioate;L319;starbld0004010;DA-64994;DGNMJYUPWDTKJB-ZDSKVHJSSA-N;LIPID L319?;EX-A5248;G16737;1351586-50-9;CS-0188740;MS-31081;GLXC-25938;LIPID L319;BP-28064;HY-139298;SCHEMBL517530;L-319， L 319 ， Lipid 319， lipid-319
SMILES	O(C(CCCN(C)C)=O)C(CCCCCCCC(=O)OC/C=C\CCCCCC)CCCCCCCC(=O)OC/C=C\CCCCCC
Formula	C41H75NO6
M.Wt	678.037313699722
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Maier MA, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Molecular Therapy. 2013;21(8):1570-1578.

Literature guide · DC57006

Formulation & Performance

Study-specific compositions, preparation conditions and experimental outcomes for L319.

Formulations Preparation Particle data Performance Interpretation References

Evidence coverage

Previously reviewed main-article evidence is retained from the existing live-page record and reorganized by species and assay. Primary search text freshly corroborates N/P 3 and approximately 10:1 total lipid:siRNA loading. Main PDF/SI retrieval was blocked, so the present update does not claim a new complete primary or SI re-review.

1. Formulations and component amounts

Reported composition and calculated mass are separate. Molecular-weight inputs use catalog values or an explicitly identified reference average; DMG-PEG2000 uses 2507. Edit inputs only when using a verified alternative material.

L319 four-component siRNA LNP

mol%Main Materials and Methods, LNP formulation; previously reviewed record retained

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
L319	55.000	85.9010	58.2441
DSPC	10.000	15.6184	12.3409
Cholesterol	32.500	50.7597	19.6262
DMG-PEG2000	2.500	3.9046	9.7888

Calculated total: 100.0000 mg lipid. RNA, solvent and process loss are excluded.

DMG-PEG2000 uses 2507 for component calculations. L319 uses the existing catalog molecular-weight value of 678.037313699722; its structure and salt-form basis have not been independently reverified in this review.

How component weights are calculated

For total lipid mass M (mg), molar parts rᵢ and molecular weight MWᵢ: component mass = M × rᵢ × MWᵢ / Σ(r × MW). Component amount (µmol) = component mass (mg) × 1000 / MWᵢ. Molar parts are normalized only for the displayed percentage. The calculation does not infer N/P or RNA dose.

2. Preparation and experimental setup

Parameter	Reported procedure / limitation	Source
Organic and aqueous phases	Lipids in ethanol; siRNA approximately 1 mg/mL in 10 mM citrate buffer, pH 4.	Main Methods; retained prior extraction
N/P and mass loading	Lipid nitrogen:siRNA phosphate ratio 3, corresponding to approximately 10:1 total lipid:siRNA by mass. The mass ratio includes all four lipids.	Main Methods; fresh primary-indexed text corroborates both bases
Mixing	Spontaneous vesicle formation through a union connector; aqueous siRNA stream 15 mL/min and ethanol lipid stream 5 mL/min.	Main Methods; retained prior extraction
Buffer exchange	Ethanol removal and PBS exchange by dialysis or tangential-flow diafiltration. PBS: 155 mM NaCl, 3 mM Na2HPO4, 1 mM KH2PO4, pH 7.5.	Main Methods; retained prior extraction
Filtration	0.2 µm sterile filtration after formulation/buffer exchange.	Main Methods; retained prior extraction
Process interpretation	The reported 3:1 aqueous:ethanol flow ratio is a volumetric mixing setting, not N/P or lipid molar composition.	Derived explanation of the reported method

3. Particle characterization

Measurement / batch	Reported result	Evidence context
Apparent LNP pKa	6.38, TNS titration	Main Table1; retained prior extraction
Particle diameter	Approximately 60 nm	Main Results/Methods; retained prior extraction
siRNA entrapment	Greater than 90%	Main Results/Methods; retained prior extraction
Mouse FVII ED50	Less than 0.01 mg/kg siRNA	Main Table1/Fig.2; 48 h hepatic Factor VII protein endpoint; not a human dose

4. Performance by experiment

Find an experiment

Experiment and dose	Readout and comparator	Result and source
Mouse Factor VII silencing C57BL/6 mice; intravenous anti-FVII siRNA at 0.01, 0.03 and 0.1 mg/kg; n=3	Readout: 48 h Comparator: Baseline/control-siRNA and lipid comparisons in the primary study	Approximately 75% FVII silencing at 0.01 mg/kg; reported ED50 below 0.01 mg/kg.Main Table1 and Fig.2; retained prior extraction
Mouse plasma lipid pharmacokinetics L319 LNP at 0.3 mg/kg siRNA intravenously; n=2 per time point	Readout: 0–8 h Comparator: Time-zero/early postdose levels	Plasma L319 decreased more than 1,000-fold in 4 h; below the 0.8 pmol/mL quantitation limit by 8 h. Estimated plasma half-life under 30 min.Main Results, Fig.3; retained prior extraction
Mouse liver lipid and metabolite kinetics L319 LNP at 0.3 mg/kg siRNA intravenously; n=2 per time point	Readout: Up to 48 h Comparator: Early postdose liver levels	Liver L319 decreased approximately 1,000-fold by 24 h and fell below quantitation by 48 h. Monoacid and diacid metabolites were detected and rapidly eliminated.Main Results, Fig.3; retained prior extraction
Rat radiolabel elimination Radiolabeled-lipid LNP study in rats; n=4; exact administered dose not recovered in this pass	Readout: 24–72 h Comparator: Injected radiolabel balance	Nearly the entire injected radiolabel was eliminated by 72 h, predominantly during the first 24 h through urine and feces. This is radiolabel recovery and does not prove excretion entirely as unchanged L319.Main Results, Fig.4; retained prior extraction
Rat tolerability Sprague-Dawley rats; single intravenous siRNA-LNP doses 1, 3, 5 or 10 mg/kg; n=5 per group	Readout: Study-specific clinical chemistry and tolerability observations Comparator: L343 comparator and study controls	L319 LNP was reported well tolerated through 10 mg/kg siRNA under the tested conditions. The 10 mg/kg figure refers to siRNA cargo dose and is not a general safe dose for neat L319.Main Results, Fig.5; retained prior extraction
Monkey hepatic TTR silencing Cynomolgus monkeys; anti-TTR siRNA 0.3 mg/kg; 15-minute intravenous infusion; n=3	Readout: 48 h liver biopsy Comparator: Control treatment in the primary study	Approximately 70% hepatic TTR mRNA silencing.Main Results, Fig.6; retained prior extraction

Mechanistic evidence

L319 was developed as a biodegradable ionizable lipid. Ester-containing hydrophobic portions support conversion to monoacid and diacid metabolites, consistent with the observed rapid parent-lipid disappearance and radiolabel elimination. Lipid clearance and pharmacodynamic siRNA silencing are different endpoints; rapid carrier clearance does not imply an equally short silencing effect.

5. Interpretation and unresolved details

N/P 3 and approximately 10:1 total lipid:siRNA describe different loading bases. Neither is a 10:1 L319-only mass ratio.
Particle pKa, diameter and entrapment apply to the studied LNP, not the isolated chemical.
Mouse Factor VII ED50, mouse lipid kinetics, rat elimination, rat tolerability and monkey TTR knockdown remain separate experiments.
Rat radiolabel recovery measures label-derived material and metabolites; avoid presenting it as unchanged parent-lipid clearance.
The reported rat tolerability ceiling is siRNA mg/kg under a single-study protocol, not a clinical dose or product safety specification.
These data support a hepatic siRNA delivery reference formulation; the 2013 study does not by itself establish mRNA, in vivo CAR-T or T-cell engager performance.

Results apply to the stated LNP composition, cargo, process, dose, route and model. LNP experimental measurements are not batch-release specifications for the isolated lipid.

6. References and data access

Maier MA, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21(8):1570–1578.

DOI: 10.1038/mt.2013.124

Download experiment table (CSV) · Open printable Formulation & Performance guide

Revision FP-20261024-b3 · Source review: 24 October 2026 · DC Chemicals

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Lipid component weights only. PEG-DMG is represented by the website-standard editable MW 2507. RNA, buffer, solvent, process loss, N/P and the approximately 10:1 total lipid:siRNA ratio are not included in the lipid-component total.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	14.7485 mL	2.9497 mL	1.4748 mL
25 mg	36.8711 mL	7.3742 mL	3.6871 mL
50 mg	73.7423 mL	14.7485 mL	7.3742 mL
100 mg	147.4845 mL	29.4969 mL	14.7485 mL
250 mg	368.7113 mL	73.7423 mL	36.8711 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

L319

Pack size & price

Description & Application

Recommended Products

DLin-MC3-DMA

ATX-126(ATX-0126, lipid 10p)

C12-200

LP-01

SM-102

TCL053

Lipid 5D8

CKK-E12

5A2-SC8

FTT5